Okahara Koki, Ishikawa Dai, Nomura Kei, Ito Shoko, Haga Keiichi, Takahashi Masahito, Shibuya Tomoyoshi, Osada Taro, Nagahara Akihito
Department of Gastroenterology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
J Clin Med. 2020 May 31;9(6):1650. doi: 10.3390/jcm9061650.
We previously demonstrated that fresh fecal microbiota transplantation (FMT) following triple antibiotic therapy (amoxicillin, fosfomycin, metronidazole (AFM); A-FMT) resulted in effective colonization of Bacteroidetes species, leading to short-term clinical response in ulcerative colitis (UC). Its long-term efficacy and criteria for donor selection are unknown. Here, we analyzed the long-term efficacy of A-FMT compared to AFM monotherapy (mono-AFM). AFM was administered to patients with mild to severe UC for 2 weeks until 2 days before fresh FMT. Clinical response and efficacy maintenance were defined by the decrease and no exacerbation in clinical activity index. The population for intention-to-treat analysis comprised 92 patients (A-FMT, = 55; mono-AFM, = 37). Clinical response was observed at 4 weeks post-treatment (A-FMT, 56.3%; mono-AFM, 48.6%). Maintenance rate of responders at 24 months post-treatment was significantly higher with A-FMT than mono-AFM ( = 0.034). Significant differences in maintenance rate according to the age difference between donors and patients were observed. Additionally, sibling FMT had a significantly higher maintenance rate than parent-child FMT. Microbial analysis of patients who achieved long-term maintenance showed that some exhibited similarity to their donors, particularly Bacteroidetes species. Thus, A-FMT exhibited long-term efficacy. Therefore, matching between donors and UC patients may be helpful in effectively planning the FMT regimen.
我们之前证明,三联抗生素疗法(阿莫西林、磷霉素、甲硝唑(AFM);A-FMT)后进行新鲜粪便微生物群移植(FMT)可有效定植拟杆菌属物种,从而在溃疡性结肠炎(UC)中产生短期临床反应。其长期疗效和供体选择标准尚不清楚。在此,我们分析了A-FMT与AFM单一疗法(单一AFM)相比的长期疗效。对轻至重度UC患者给予AFM治疗2周,直至新鲜FMT前2天。临床反应和疗效维持通过临床活动指数的降低和无恶化来定义。意向性分析人群包括92例患者(A-FMT组,n = 55;单一AFM组,n = 37)。治疗后4周观察到临床反应(A-FMT组,56.3%;单一AFM组,48.6%)。A-FMT组治疗后24个月反应者的维持率显著高于单一AFM组(P = 0.034)。观察到根据供体与患者之间的年龄差异,维持率存在显著差异。此外,同胞FMT的维持率显著高于亲子FMT。对实现长期维持的患者进行的微生物分析表明,一些患者与供体表现出相似性,尤其是拟杆菌属物种。因此,A-FMT显示出长期疗效。因此,供体与UC患者之间的匹配可能有助于有效规划FMT方案。